DOCSLIB.ORG

Treatment of Thyrotoxicosis Resistant to Carbimazole with Corticosteroids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment of Thyrotoxicosis Resistant to Carbimazole with Corticosteroids Prednisolone treatment in thyrotoxicosis 489 Postgrad Med J: first published as 10.1136/pgmj.72.850.489 on 1 August 1996. Downloaded from Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids EB Jude, J Dale, S Kumar, PM Dodson Summary 37 pmol/l (normal 1-24 pmolIl), free triiodo- We report two patients whose thyrotox- thyronine of 12.7 pmolIl (4.2-7.1 pmolIl) and icosis failed to respond to conventional thyroid stimulating hormone of 0.2 mU/l treatment with carbimazole. The patients (0.3-3.8 mU/l). Thyroid antimicrosomal and remained persistently hyperthyroid, both antithyroglobulin antibody titres were 1:400 clinically and biochemically, despite sev- and negative, respectively. She was treated with eral months of carbimazole therapy at the carbimazole 30 mg daily but two months later maximum recommended doses. Predni- she was still clinically thyrotoxic and her free solone 20 mg per day was then given in thyroxine was 41.6 pmol/l. The carbimazole addition to the antithyroid drug and a was increased to 60 mg daily. She was also dramatic reponse observed in both cases. prescribed propranolol but it had to be They were then successfully treated with discontinued owing to respiratory wheeze. radioiodine. Four months later, on the maximum recom- Prednisolone has not been previously mended dose of carbimazole, she felt no better used to treat patients with hyperthyroid- and her free thyroxine was 46 pmol/l. Non- ism who have not responded to thiona- compliance with the prescribed medication mide drugs. Our experience suggests that was suspected, but on repeated questioning corticosteroids may be potentially useful she asserted that she was taking her treatment for controlling thyrotoxicosis in combina- regularly. She was then started on predniso- tion with carbimazole before definite lone 20 mg daily in addition to the carbima- treatment can be instituted. zole. There was marked improvement in her symptoms within four weeks and she was Keywords: thyrotoxicosis, prednisolone, carbimazole clinically euthyroid, which was confirmed with resistance a free thyroxine of 28.8 pmol/l. At this stage she was given radioactive iodine 400 MBq. Two months later her free thyroxine was Thionamides have been used in the treatment 17.7 pmol/l (figure). The carbimazole was then of hyperthyroidism for over 50 years. Most stopped and prednisolone was gradually with- http://pmj.bmj.com/ patients respond within four to six weeks of drawn; 15 months hence she is euthyroid and initiating treatment and the dose is reduced to clinically well. a maintenance level for a further six to 12 months. Rarely, patients are found not to Case 2 respond to antithyroid drugs (carbimazole or A 46-year-old woman presented with symp- propylthiouracil) and this poses a difficult toms of tremors, weight loss, tiredness, in- management Such are usual- problem. patients creased sweating, irritability and inability to on September 28, 2021 by guest. Protected copyright. ly thought to have failed to comply with their concentrate at work. On examination she had a medication. Corticosteroids are often used in the man- agement of thyroid crisis.' However, they have prednisolone not been recognised as useful therapy in the 140- management of patients not responding to antithyroid drugs alone. We report two pa- 120 - tients who remained persistently thyrotoxic E0100 / \ RAI despite treatment with carbimazole at the E recommended dose for four months. r- 80 Department of Q 80-cX S pednisoone Medicine, 0) Birmingham Heart- Case 1 lands Hospital, A 30-year-old woman had had symptoms of Birmingham thyrotoxicosis with palpitations, mood B9 5SS, UK changes, heat intolerance, weight loss and 0 EB Jude J Dale diarrhoea for six months. On examination she ' S Kumar was lean (body mass index 19), and had sinus 0 3 6 9 12 15 18 21 24 PM Dodson tachycardia with a heart rate of 120 beats/min. time (months) She had a diffuse goitre with a bruit and fine Correspondence to tremor of her hands, but no eye signs apart Figure Serum free thyroxine concentrations for Case Dr PM Dodson 1 (0) and Case 2 (0) during treatment with from lid lag. Thyroid function tests confirmed carbimazole and the effect of adding prednisolone. Accepted 13 November 1995 hyperthyroidism with free thyroxine of RAI=radioactive iodine 490 Jude, Dale, Kumar, Dodson diffuse goitre with an audible bruit, but no eye signs of Graves' disease. Her pulse rate was Summarynlearning points 100 beats/min, regular. She had fine tremors of * resistance to antithyroid drugs in the treatment Postgrad Med J: first published as 10.1136/pgmj.72.850.489 on 1 August 1996. Downloaded from her fingers and mild proximal muscle weak- of thyrotoxicosis is not unknown ness. Thyroid function tests confirmed thyro- * prednisolone has been shown to ameliorate the toxicosis (serum free thyroxine 73.8 pmol/l, symptoms of hyperthyroidism and hence can free triiodothyronine > 43.2 pmol/l and thyroid be used as an adjunct in the treatment of stimulating hormone < 0.1 mU/l). Her antimi- thyrotoxicosis when patients do not respond to crosomal and antithyroglobulin antibody titres antithyroid drugs alone * prednisolone can also be useful in the rapid were 1: 25 600 and negative, respectively. She control of symptoms in the elderly and when was started on carbimazole 45 mg daily which, definitive treatment for thyrotoxicosis has been three months later was increased to 60 mg daily planned, such as radioiodine because of persistent hyperthyroidism. Two months later her serum free thyroxine was > 125 pmol/l and her symptoms had worsened. She denied noncompliance to treatment. She was then commenced on prednisolone 20 mg measures to reduce their serum free thyroxine daily in addition to the carbimazole. In the next concentration. In our two patients we used two weeks her symptoms had improved and she prednisolone to good effect. The addition of was able to go back to work. Four and eight prednisolone as an adjunct to carbimazole weeks later her free thyroxine was 71.2 and produced significant clinical improvement 63.6 pmol/l, respectively. In view of the con- and made it safe for the patients to have siderable improvement in symptoms and since radioiodine treatment. the free thyroxine level was down to 50% of her Prednisolone is not used as a mode of levels prior to prednisolone, she received radio- achieving euthyroid status in patients with active iodine 400 MBq. Four and six months hyperthyroidism, though it is often used in later her free thyroxine was 44.9 pmol/l and thyroid crisis. Studies have shown a rapid 5 pmol/l (figure). The carbimazole was there- decline in serum thyroid hormone concentra- fore discontinued and prednisolone was gradu- tion following the acute administration of ally withdrawn. She is now being treated with glucocorticoids.4-7 The effect of corticoster- thyroxine owing to hypothyroidism and is well. oids on the thyroid gland in hyperthyroidism is obscure. Graves' disease is an autoimmune Discussion disorder,' both cell- and antibody-mediated.8 The latter is a syndrome complex due to the Carbimazole is widely used in the management action on the thyroid of IgG immunoglobulins of hyperthyroidism. It acts by inhibiting the that may be antibodies against components or oxidation and organic binding of thyroid regions of the thyroid plasma membrane, iodide" 2 as well as having an immunosuppres- possibly regions that include the receptor for sive effect upon the thyroid itself. It is some thyroid stimulating hormone itself. Thus, the months before the patient is rendered euthyr- reason why patients respond to corticosteroids oid, therefore compliance with treatment is could be two-fold. The more immediate effect http://pmj.bmj.com/ essential. Failure to take the medication is could be the inhibition of conversion of generally thought to be the reason for lack of thyroxine to triiodothyronine in the peripheral response to treatment, but the true prevalence tissue,5 blocking the release of thyroxine from of carbimazole resistance is unknown. There the thyroid. It may also lead to suppression of are few reports in the literature of patients not the immune response and hence decreased responding to the maximum recommended stimulation of the thyroid gland by the altered dose of 60 mg carbimazole daily.' It is not clear immune response and cell-mediated immu- on September 28, 2021 by guest. Protected copyright. why such patients do not respond. Both our nity. Clearly, further studies are needed to patients denied noncompliance. Our first examine the effect of such immunosuppressive patient also had diarrhoea but there was no therapy in Graves' disease. clinical evidence to suggest malabsorption. Our experience suggests that there are some Although it is possible to measure drug levels, patients who may benefit from the use of this is rarely done in clinical practice and was corticosteroids as an adjunct to antithyroid not performed in our patients. However, the drugs in the treatmnent of Graves' disease. Such observation that both patients demonstrated patients would include those in whom the significant improvement once given predniso- response to carbimazole has been poor and lone suggests that compliance was unlikely to also those patients in whom rapid remission of have been the problem. the disease is required, such as in the elderly Before definitive treatment of thyrotoxicosis and in patients with thyrotoxic heart disease. with subtotal thyroidectomy or ablation with These cases demonstrate the potential value of radioiodine, it is necessary to control hy- prednisolone in rapid control ofthyrotoxicosis, perthyroidism so as to reduce the risk of where a decision has been made to proceed precipitating thyroid crisis.'l Hence patients with definitive treatment such as surgery or not responding to carbimazole need fulrther radioiodine. 1 Wilson JD, Foster DW. Textbook of endocrinology, 8th edn.
Load more

Recommended publications
  • Radionuclide Thyroid Scans
    Radionuclide Thyroid Scans Report 2003 1 Purpose The purpose of this guideline is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting radionuclide thyroid scans. This guideline will assist individual departments in the formulation of their own local protocols. Background Thyroid scintigraphy is an effective imaging method for assessing the functionality of thyroid lesions including the uptake function of part or all of the thyroid gland. 99TCm pertechnetate is trapped by thyroid follicular cells. 123I-Iodide is both trapped and organified by thyroid follicular cells. Common Indications 1.1 Assessment of functionality of thyroid nodules. 1.2 Assessment of goitre including hyperthyroid goitre. 1.3 Assessment of uptake function prior to radio-iodine treatment 1.4 Assessment of ectopic thyroid tissue. 1.5 Assessment of suspected thyroiditis 1.6 Assessment of neonatal hypothyroidism Procedure 1 Patient preparation 1.1 Information on patient medication should be obtained prior to undertaking study. Patients on Thyroxine (Levothyroxine Sodium) should stop treatment for four weeks prior to imaging, patients on Tri-iodothyronine (T3) should stop treatment for two weeks if adequate images are to be obtained. 1.2 All relevant clinical history should be obtained on attendance, including thyroid medication, investigations with contrast media, other relevant medication including Amiodarone, Lithium, kelp, previous surgery and diet. 1.3 All other relevant investigations should be available including results of thyroid function tests and ultrasound examinations. 1.4 Studies should be scheduled to avoid iodine-containing contrast media prior to thyroid imaging. 2 1.5 Carbimazole and Propylthiouracil are not contraindicated in patients undergoing 99Tcm pertechnetate thyroid scans and need not be discontinued prior to imaging.
    [Show full text]
  • Evaluating and Managing Patients with Thyrotoxicosis
    Thyroid Evaluating and Kirsten Campbell managing patients with Matthew Doogue thyrotoxicosis Background Thyrotoxicosis is common in the Australian population Thyrotoxicosis is common in the Australian community and and thus a frequent clinical scenario facing the general is frequently encountered in general practice. Graves disease, practitioner. The prevalence of thyrotoxicosis (subclinical toxic multinodular goitre, toxic adenoma and thyroiditis or overt) reported among those without a history of thyroid account for most presentations of thyrotoxicosis. disease in Australia is approximately 0.5% and this Objective increases with age.1,2 This article outlines the clinical presentation and evaluation of a patient with thyrotoxicosis. Management of Graves disease, Causes of thyrotoxicosis the most frequent cause of thyrotoxicosis, is discussed in Table 1 outlines the various causes of thyrotoxicosis. The most further detail. common cause is Graves disease followed by toxic multinodular Discussion goitre, the latter increasing in prevalence with age and iodine The classic clinical manifestations of thyrotoxicosis are deficiency.3,4 Other important causes include toxic adenoma and often easily recognised by general practitioners. However, thyroiditis. Exposure to excessive amounts of iodine (eg. iodinated the presenting symptoms of thyrotoxicosis are varied, with computed tomography [CT] contrast media, amiodarone) in the atypical presentations common in the elderly. Following presence of underlying thyroid disease, especially multinodular biochemical confirmation of thyrotoxicosis, a radionuclide goitre, can cause iodine induced thyrotoxicosis. Thyroiditis thyroid scan is the most useful investigation in diagnosing is a condition that may be suitable for management in the the underlying cause. The selection of treatment differs general practice setting. Patients should be monitored for the according to the cause of thyrotoxicosis and the wishes of the hypothyroid phase, which may occur with this condition.
    [Show full text]
  • Neo-Mercazole
    NEW ZEALAND DATA SHEET 1 NEO-MERCAZOLE Carbimazole 5mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5mg of carbimazole. Excipients with known effect: Sucrose Lactose For a full list of excipients see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM A pale pink tablet, shallow bi-convex tablet with a white centrally located core, one face plain, with Neo 5 imprinted on the other. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Primary thyrotoxicosis, even in pregnancy. Secondary thyrotoxicosis - toxic nodular goitre. However, Neo-Mercazole really has three principal applications in the therapy of hyperthyroidism: 1. Definitive therapy - induction of a permanent remission. 2. Preparation for thyroidectomy. 3. Before and after radio-active iodine treatment. 4.2 Dose and method of administration Neo-Mercazole should only be administered if hyperthyroidism has been confirmed by laboratory tests. Adults Initial dosage It is customary to begin Neo-Mercazole therapy with a dosage that will fairly quickly control the thyrotoxicosis and render the patient euthyroid, and later to reduce this. The usual initial dosage for adults is 60 mg per day given in divided doses. Thus: Page 1 of 12 NEW ZEALAND DATA SHEET Mild cases 20 mg Daily in Moderate cases 40 mg divided Severe cases 40-60 mg dosage The initial dose should be titrated against thyroid function until the patient is euthyroid in order to reduce the risk of over-treatment and resultant hypothyroidism. Three factors determine the time that elapses before a response is apparent: (a) The quantity of hormone stored in the gland. (Exhaustion of these stores usually takes about a fortnight).
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • Management of Hyperthyroidism During Pregnancy and Lactation
    European Journal of Endocrinology (2011) 164 871–876 ISSN 0804-4643 REVIEW Management of hyperthyroidism during pregnancy and lactation Fereidoun Azizi and Atieh Amouzegar Research Institute for Endocrine Sciences, Endocrine Research Center, Shahid Beheshti University (MC), PO Box 19395-4763, Tehran 198517413, Islamic Republic of Iran (Correspondence should be addressed to F Azizi; Email: [email protected]) Abstract Introduction: Poorly treated or untreated maternal overt hyperthyroidism may affect pregnancy outcome. Fetal and neonatal hypo- or hyper-thyroidism and neonatal central hypothyroidism may complicate health issues during intrauterine and neonatal periods. Aim: To review articles related to appropriate management of hyperthyroidism during pregnancy and lactation. Methods: A literature review was performed using MEDLINE with the terms ‘hyperthyroidism and pregnancy’, ‘antithyroid drugs and pregnancy’, ‘radioiodine and pregnancy’, ‘hyperthyroidism and lactation’, and ‘antithyroid drugs and lactation’, both separately and in conjunction with the terms ‘fetus’ and ‘maternal.’ Results: Antithyroid drugs are the main therapy for maternal hyperthyroidism. Both methimazole (MMI) and propylthiouracil (PTU) may be used during pregnancy; however, PTU is preferred in the first trimester and should be replaced by MMI after this trimester. Choanal and esophageal atresia of fetus in MMI-treated and maternal hepatotoxicity in PTU-treated pregnancies are of utmost concern. Maintaining free thyroxine concentration in the upper one-third of each trimester-specific reference interval denotes success of therapy. MMI is the mainstay of the treatment of post partum hyperthyroidism, in particular during lactation. Conclusion: Management of hyperthyroidism during pregnancy and lactation requires special considerations andshouldbecarefullyimplementedtoavoidanyadverse effects on the mother, fetus, and neonate. European Journal of Endocrinology 164 871–876 Introduction hyperthyroidism during pregnancy is of utmost import- ance.
    [Show full text]
  • Hypothyroidism – Investigation and Management
    Thyroid Hypothyroidism Investigation and management Michelle So Richard J MacIsaac Mathis Grossmann Background Hypothyroidism is one of the most common endocrine Hypothyroidism is a common endocrine disorder that mainly disorders, with a greater burden of disease in women affects women and the elderly. and the elderly.1 A 20 year follow up survey in the Objective United Kingdom found the annual incidence of primary This article outlines the aetiology, clinical features, hypothyroidism to be 3.5 per 1000 in women and 0.6 per 2 investigation and management of hypothyroidism. 1000 in men. A cross sectional Australian survey found the prevalence of overt hypothyroidism to be 5.4 per 1000.3 Discussion In the Western world, hypothyroidism is most commonly Aetiology caused by autoimmune chronic lymphocytic thyroiditis. The initial screening for suspected hypothyroidism is thyroid Iodine deficiency remains the most common cause of hypothyroidism 4 stimulating hormone (TSH). A thyroid peroxidase antibody worldwide. However, in Australia and other iodine replete countries, assay is the only test required to confirm the diagnosis of autoimmune chronic lymphocytic thyroiditis is the most common autoimmune thyroiditis. Thyroid ultrasonography is only aetiology.5 indicated if there is a concern regarding structural thyroid The main causes of hypothyroidism and associated clinical features abnormalities. Thyroid radionucleotide scanning has no are shown in Table 1. role in the work-up for hypothyroidism. Treatment is with thyroxine replacement (1.6 µg/kg lean body weight daily). When to suspect hypothyroidism Poor response to treatment may indicate poor compliance, Symptoms are influenced by the severity of the hypothyroidism, as drug interactions or impaired absorption.
    [Show full text]
  • SDC 1. Supplementary Notes to Methods Settings Groote Schuur
    Mouton JP, Njuguna C, Kramer N, Stewart A, Mehta U, Blockman M, et al. Adverse drug reactions causing admission to medical wards: a cross-sectional survey at four hospitals in South Africa. Supplemental Digital Content SDC 1. Supplementary notes to Methods Settings Groote Schuur Hospital is a 975-bed urban academic hospital situated in Cape Town, in the Western Cape province, which provides secondary and tertiary level care, serves as a referral centre for approximately half of the province’s population (2011 population: 5.8 million)1 and is associated with the University of Cape Town. At this hospital we surveyed the general medical wards during May and June 2013. We did not survey the sub-speciality wards (dermatology, neurology, cardiology, respiratory medicine and nephrology), the oncology wards, or the high care / intensive care units. Restricting the survey to general medical wards was done partly due to resource limitations but also to allow the patients at this site to be reasonably comparable to those at other sites, which did not have sub-specialist wards. In 2009, the crude inpatient mortality in the medical wards of Groote Schuur Hospital was shown to be 573/3465 patients (17%)2 and the 12-month post-discharge mortality to be 145/415 (35%).3 Edendale Hospital is a 900-bed peri-urban regional teaching hospital situated near Pietermaritzburg, in the KwaZulu-Natal province (2011 population: 10.3 million).1 It provides care to the peri-urban community and serves as a referral centre for several district hospitals in the surrounding rural area. It is located at the epicentre of the HIV, tuberculosis and multidrug resistant tuberculosis epidemics in South Africa: a post-mortem study in 2008-2009 found that 94% of decedents in the medical wards of Edendale Hospital were HIV-seropositive, 50% had culture-positive tuberculosis at the time of death and 17% of these cultures were resistant to isoniazid and rifampicin.4 At Edendale Hospital, we surveyed the medical wards over 30 days during July and August of 2013.
    [Show full text]
  • Thyroid Function Tests During Carbimazole Therapy D
    Postgraduate Medical Journal (December 1980) 56, 838-841 Postgrad Med J: first published as 10.1136/pgmj.56.662.838 on 1 December 1980. Downloaded from Thyroid function tests during carbimazole therapy D. L. SCOTT D. J. TYMMS M.R.C.P. M.R.C.P. M. A. TAYLOR C. CHAPMAN M.R.C.P. Ph.D. The Department of Nuclear Medicine, The General Infirmary, Leeds Summary therapy in 100 patients with Graves' disease, and Changes in plasma thyroxine (T4), triiodothyronine evaluated their clinical relevance. (T3), free thyroxine index (FT4I) and thyroid stimu- lating hormone were studied in 100 patients with Patients and methods Graves' disease treated with carbimazole. During One hundred patients with Graves' disease who therapy plasma T3 concentrations were disproportion- were clinically thyrotoxic with raised plasma T4 and ately high compared to those of T4, the T4 : T3 ratio T3 concentrations before treatment were included. was and were Those who had had destructive to low, many patients clinically euthyroid previous therapy Protected by copyright. with a normal plasma T3 but low T4 concentration. the thyroid were excluded. All had at least 6 months' Although there was considerable individual variation treatment with carbimazole, starting with doses of in response, the order of response was always the at least 40 mg daily and reduced to a maintenance same with plasma T4 falling to normal or low levels dose of 5-20 mg daily. Eighteen were consecutive before T3. Plasma T3 was the best indicator of clinical patients with Graves' disease who were studied status and the best predictor of impending change; prospectively from 1973-75 (group A).
    [Show full text]
  • Carbimazole Or Thiamazole (Synonym: Methimazole): (1) Strengthened Advice on Contraception and (2) Risk of Acute Pancreatitis
    16-Jan-2019 Medicinal products containing carbimazole or thiamazole (synonym: methimazole): (1) strengthened advice on contraception and (2) risk of acute pancreatitis Dear Healthcare professional, Amdipharm Limited and Essential-Healthcare Ltd in agreement with the European Medicines Agency and the Health Products Regulatory Authority (HPRA) would like to inform you of the following: Summary (1) Strengthened advice on contraception • New review of available evidence from epidemiological studies and case reports strengthens the evidence that carbimazole/ thiamazole is suspected to cause congenital malformations when administered during pregnancy, particularly in the first trimester of pregnancy and at high doses. • Women of childbearing potential have to use effective contraceptive measures during treatment with carbimazole/ thiamazole. • Hyperthyroidism in pregnant women should be adequately treated to prevent serious maternal and foetal complications. • Carbimazole/thiamazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones. • If carbimazole/thiamazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended. (2) Risk of acute pancreatitis • Acute pancreatitis has been reported following treatment with carbimazole/thiamazole. • If acute pancreatitis occurs, treatment with carbimazole/ thiamazole should be discontinued immediately. • As re-exposure may result in recurrence of acute pancreatitis, with decreased time to onset, these medicines must not be given to patients with a history of acute pancreatitis following administration of carbimazole/thiamazole. Background on the safety concern General information Medicinal products containing carbimazole or thiamazole are used in the management of hyperthyroidism, preparation for thyroidectomy in hyperthyroidism and therapy prior to and post radio-iodine treatment.
    [Show full text]
  • Medicines Management in Thyroid Disease
    Medicines Management in Thyroid Disease Janet Corbett Head of Prescribing and Medicines Management Milton Keynes Clinical Commissioning Group (CCG) “To get the best value from medicines for patients and the NHS” What is the thyroid and why is it important? Small butterfly shaped gland in neck, wrapped around windpipe Produces several hormones – most important are liothyronine T3 and levothyroxine T4 These hormones help oxygen get into the cells and so affect metabolism by helping cells convert oxygen and calories into energy Concentrations of T3 and T4 are regulated by thyroid stimulating hormone (TSH) When thyroid hormone levels increase, TSH production decreases and vice versa Euthyroid = normal TSH, T3 and T4 levels Hypothyroid = low levels of T3 and T4 and high TSH Hyperthyroidism = high levels of T3 and T4 and undetectable levels of TSH “To get the best value from medicines for patients and the NHS” Aims of treatment To achieve a normal thyroid-stimulating hormone (TSH) level To reduce complications To improve quality of life “To get the best value from medicines for patients and the NHS” Hypothyroidism Treatment of choice – levothyroxine (T4) Life long treatment Levothyroxine and liothyronine (T3) in combination or dried thyroid extracts are probably no better than levothyroxine alone Liothyronine – shorter acting; may be helpful in severe hypothyroid states Starting dose of levothyroxine is 50 to 100 micrograms once a day; may be increased to 200 micrograms once a day. Lower doses eg 25mcg may be used in the elderly
    [Show full text]
  • The Outcome of a Calculated Radioiodine Dose Based On
    Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346) ORIGINAL ARTICLE The Outcome Of A Calculated Radioiodine Dose Based On Pertechnetate Thyroid Uptake Ratio In Treatment For Hyperthyroidism Lee Yeong Fong1,2, Ibrahim Lutfi Shuaib2, Fadzilah Hamzah1 1 Nuclear Medicine Department, Hospital Pulau Pinang, 10990 George Town, Pulau Pinang, Malaysia 2 Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia ABSTRACT Introduction: There are two dosing methods for radioiodine dose administration including empirical fixed dose and calculated dose. Recent meta-analysis supported that dose calculation is better than empirical fixed dose. However, dose calculation by dosimetry or 24 hours radioiodine uptake ratio can be tedious. Pertechnetate thyroid scintig- raphy is a simple nuclear imaging that can be completed on the same day and pertechnetate thyroid uptake ratio determined from the scintigraphy can be used to calculate the radioiodine dose. This research is done to measure the efficacy of the calculated dose regime. Methods: Hyperthyroidism patients referred for first radioiodine therapy were recruited. Pertechnetate thyroid scintigraphy was done and pertechnetate uptake ratio used for dose calculation. The outcome of the treatment was determined at six months. Results: A total of 95 patients were recruited. Six months after treatment, 82.1% of the calculated dose cohort achieved euthyroid or hypothyroid state. Participants with mul- tinodular goitre had higher failure rate than those with Graves’ disease (p=0.032) although there was no difference in the median RAI dose given (p=0.866). Conclusion: This calculated dose method showed good outcome with 82.1% cure rate at six months post treatment.
    [Show full text]
  • The Selection and Use of Essential Medicines
    WHO Technical Report Series 958 THE SELECTION AND USE OF ESSENTIAL MEDICINES This report presents the recommendations of the WHO Expert THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a review of the OF ESSENTIAL MEDICINES report of the meeting of the Expert Subcommittee on the Selection and Use of Essential Medicines, held in October 2008. It also provides details of new applications for paediatric medicines and summarizes the Committee’s considerations and justifi cations for additions and changes to the Model List, including its recommendations. Part Two of the publication is the report of the second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Annexes include the revised version of the WHO Model List of Essential Medicines (the 16th) and the revised version of the WHO Model List of Report of the WHO Expert Committee, 2009 Essential Medicines for Children (the 2nd). In addition there is a list of all the items on the Model List sorted according to their (including the 16th WHO Model List of Essential Medicines Anatomical Therapeutic Chemical (ATC) classifi cation codes. and the 2nd WHO Model List of Essential Medicines for Children) WHO Technical Report Series — 958 WHO Technical ISBN 978-92-4-120958-8 Geneva TTRS958cover.inddRS958cover.indd 1 110.06.100.06.10 008:328:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health.
    [Show full text]